The expanding field of cannabimimetic and related lipid mediators

British Journal of Pharmacology

Volumn 144, Issue 4, 2005, Pages 459-465

  Bradshaw, Heather B ^a   Walker, J Michael ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Acyl ethanolamide; Arachidonoyl dopamine; Arachidonoyl glycine; Cannabinoid; Cyclooxygenase; Lipid mediator; Oleoyl dopamine

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 LINOLEOYLGLYCEROL; 2 PALMITOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CYTOCHROME P450; DOPAMINE DERIVATIVE; FENTANYL; GLYCEROL DERIVATIVE; INTERLEUKIN 2; LINOLEAMIDE; LIPID; LIPOXYGENASE; LOPERAMIDE; N ARACHIDONOYLDOPAMINE; N ARACHIDONOYLGLYCINE; N OLEOYLETHANOLAMINE; NATURAL PRODUCT; OLEAMIDE; OLEOYLDOPAMINE; PALMIDROL; PROSTAGLANDIN SYNTHASE; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BINDING AFFINITY; CARDIOVASCULAR DISEASE; DRUG POTENTIATION; EATING DISORDER; HUMAN; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; SLEEP DISORDER;

ANIMALS; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, CANNABINOID;

EID: 14844282831     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706093     Document Type: Review

References (77)

1. AHERN, G.P. (2003). Activation of TRPV1 by the satiety factor oleoylethanolamide. J. Biol. Chem., 278, 30429-30434.
2. BEN-SHABAT, S., FRIDE, E., SHESKIN, T., TAMIRI, T., RHEE, M.H., VOGEL, Z., BISOGNO, T., DE PETROCELLIS, L., DI MARZO, V. & MECHOULAM, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol., 353, 23-31.
3. BERDYSHEV, E.V. (1999). Inhibition of sea urchin fertilization by fatty acid ethanolamides and cannabinoids. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol., 122, 327-330.
4. BISOGNO, T., VENTRIGLIA, M., MILONE, A., MOSCA, M., CIMINO. G. & DI MARZO, V. (1997). Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim. Biophys. Acta, 1345, 338-348.
5. BOGER, D.L., HENRIKSEN, S.J. & CRAVATT, B.F. (1998a). Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr. Pharm. Des., 4, 303-314.
6. BOGER, D.L., PATTERSON, J.E., GUAN, X., CRAVATT, B.F., LERNER, R.A. & GILULA, N.B. (1998b). Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc. Natl. Acad. Sci. U.S.A., 95, 4810-4815.
7. BOGER, D.L., SATO, H., LERNER, A.E., GUAN, X. & GILULA, N.B. (1999). Arachidonic acid amide inhibitors of gap junction cell-cell communication. Bioorg. Med. Chem. Lett., 9, 1151-1154.
8. BRADSHAW, H.B., KREY, J.K. & WALKER, J.M. (2003). Levels of endocannabinoids and related lipid mediators in the female reproductive tract change as a function of estrous cycle. Soc. Neuro., Abstracts Online Prog. Number 464.3.
9. BURSTEIN, S.H. (1999). The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol. Ther., 82, 87-96.
10. BURSTEIN, S.H., HUANG, S.M., PETROS, T.J., ROSSETTI, R.G., WALKER, J.M. & ZURIER, R.B. (2002). Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem. Pharmacol., 64, 1147-1150.
11. BUTELMAN, E.R., BALL, J.W., HARRIS, T.J. & KREEK, M.J. (2003). Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation. J. Pharmacol. Exp. Ther., 311, 155-163.
12. BUTELMAN, E.R., HARRIS, TJ. & KREEK, M.J. (2004). Antiallodynic effects of loperamide and fentanyl against topical capsicin-induced allodyndia in unanesthetized primates. J. Pharmacol. Exp. Ther., 306, 1106-1114.
13. CALIGNANO, A., LA RANA, G., GIUFFRIDA, A. & PIOMELLI, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature. 394, 277-281.
14. CALIGNANO, A., LA RANA, G. & PIOMELLI, D. (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol., 419, 191-198.
15. CASCIO, M.G., MINASSI, A., LIGRESTI, A., APPENDINO, G., BURSTEIN, S. & DI MARZO, V. (2004). A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Comm., 314, 192-196.
16. CHU, C.J., HUANG, S.M., DE PETROCELLIS, L., BISOGNO, T., EWING, S.A., MILLER, J.D., ZIPKIN, R.E., DADDARIO, N., APPENDINO, G., DIMARZO, V. & WALKER, J.M. (2003). N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem., 278, 13633-13639.
17. CRAVATT, B.F., GIANG, D.K., MAYFIELD, S.P., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384, 83-87.
18. CRAVATT, B.F., PROSPERO-GARCIA, O., SIUZDAK, G., GILULA, N.B., HENRIKSEN, S.J., BOGER, D.L, & LERNER, R.A. (1995). Chemical characterization of a family of brain lipids that induce sleep. Science. 268, 1506-1509.
19. DE PETROCELLIS, L., DAVIS, J.B. & DI MARZO, V. (2001). Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett., 506, 253-256.
20. DE PETROCELLIS, L., CHU, C.J., MORIELLO, A.S., KELLNER, J.C., WALKER, J.M. & DI MARZO, V. (2004). Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br. J. Pharmacol., 143, 251-256.
21. DEVANE, W.A., HANUS, L. BREUER, A., PERTWEE, R.G., STEVENSON, L.A, GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
22. DI MARZO, V., DE PETROCELLIS, L., SEPE, N. & BUONO, A. (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J., 316 (Part 3), 977-984.
23. DI MARZO, V., MELCK, D., ORLANDO, P., BISOGNO, T., ZAGOORY, O., BIFULCO, M., VOGEL, Z. & DE PETROCELLIS, L. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J., 358, 249-255.
24. FACCI, L., DAL TOSO, R., ROMANELLO, S., BURIANI, A., SKAPER, S.D. & LEON, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and Palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A., 92, 3376-3380.
25. FEDOROVA, I., HASHIMOTO, A., FECIK, R.A., HEDRICK, M.P., HANUS, L.O., BOGER, D.L., RICE, K.C. & BASILE, A.S. (2001). Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther., 299, 332-342.
26. FEZZA, F., BISOGNO, T., MINASSI, A., APPENDING, G., MECHOULAM, R. & DI MARZO, V. (2002). Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett., 513, 294-298.
27. FOWLER, C.J. (2004). Oleamide: a member of the endocannabinoids family? Br. J. Pharmacol., 141, 195-196.
28. FU, J., GAETANI, S., OVEISI, F., LO VERME, J., SERRANO, A., DE FONSESCA, F.R., ROSENGARTH, A., LUECKE, H., DI GIACOMO, B., TARZIA, G. & PIOMELLI, D. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. 425, 90-93.
29. GAVVA, N.R., KLIONSKY, L., QU, Y., SHI, L., TAMIR, R., EDENSON, S., ZHANG, T.J., VISWANDADHAN, V.N., TOTH, A., PEARCE, L.V., VANDERAH, T.W., PORRECA, F., BLUMBERG, M., LILE, J., SUN, Y., WILD, K., LOUIS, J.-C. & TREANOR, J.S. (2004). Molecular determinants of vanilloid sensitivity in TRPV1. J. Biol. Chem., 279, 20283-20295.
30. GOMEZ, R., NAVARRO, M., FERRER, B., TRIGO, J.M., BILBAO, A., DEL ARCO, I., CIPPITELLI, A., NAVA, F., PIOMELLI, D., RODRIGUEZ, D.E. & FONSECA, F. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci., 22, 9612-9617.
31. GUAN, X., CRAVATT, B.F., EHRING, G.R., HALL, J.E., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1997). The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells. J. Cell. Biol., 139, 1785-1792.
32. GUZMAN, M., LO VERME, J., FU, J., OVEISI, F., BLAZQUEZ, C. & PIOMELLI, D. (2004). Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor a (PPAR-α). J. Biol. Chem., 279, 27849-27854.
33. HANUS, L., ABU-LAFI, S., FRIDE, E., BREUER, A., VOGEL, Z., SHALEV, D.E., KUSTANOVICH, I. & MECHOULAM, R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 3662-3665.
34. HANUS, L., GOPHER, A., ALMOG, S. & MECHOULAM, R. (1993). Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem., 36, 3032-3034.
35. HARRISON, S., DE PETROCELLIS, L., TREVISANI, M., BENVENUTI, F., BIFULCO, M., GEPPETTI, P. & DIMARZO, V. (2003). Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. Eur. J. Pharmacol., 475, 107-114.
36. HUANG, J.K. & JAN, C.R. (2001). Linoleamide, a brain lipid that induces sleep, increases cytosolic Ca2+ levels in MDCK renal tubular cells. Life Sci., 68, 997-1004.
37. HUANG, S.M, BISOGNO, T., PETROS, T.J., CHANG, S.Y., ZAVITSANOS, P.A., ZIPKIN, R.E., SIVAKUMAR, R., COOP, A., MAEDA, D.Y., DE PETROCELLIS, L., BURSTEIN, S., DI MARZO, V. & WALKER, J.M. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem., 276, 42639-42644.
38. HUANG, S.M., BISOGNO, T., TREVISANI, M., AL-HAYANI, A., DE PETROCELLIS, L., FEZZA, F., TOGNETTO, M., PETROS, T.J., KREY, J.F., CHU, C.J., MILLER, J.D., DAVIES, S.N., GEPPETTI, P., WALKER, J.M. & DI MARZO, V. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U.S.A., 99, 8400-8405.
39. HUIDOBRO-TORO, J.P. & HARRIS, R.A. (1996). Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors. Proc. Natl. Acad. Sci. U.S.A., 93, 8078-8082.
40. JAGGAR, S.I., HASNIE, F.S., SELLATURAY, S. & RICE, A.S. (1998). The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76, 189-199.
41. JARAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY. N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 14136-14141.
42. JONSSON, K.O., VANDEVOORDE, S., LAMBERT, D.M., TIGER, G. & FOWLER, C.J. (2001). Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol., 133, 1263-1275.
43. KARAVA, V., FASIA, L. & SIAFAKA-KAPADAI, A. (2001). Anandamide amidohydrolase activity, released in the medium by Tetrahymena pyriformis. Identification and partial characterization. FEBS Lett., 508, 327-331.
44. KOZAK, K.R., CREW, B.C., MORROW, J.D., WANG, L.H., MA, Y.H., WEINANDER, R., JAKOBSSON, P.J. & MARNETT, L.J. (2002). Metabolism of the endocannabinoids, 2-arachidonoylglycerol and anandamide, into prostaglandin. thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem., 277, 44877-44885.
45. KUEHL, F.A., JACOB, T.A., GANLEY, O.K., ORMOND, R.E. & MEISINGER, M.A.P. (1957). The identification of N-2(hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc., 79, 5577-5578.
46. LAINE, K., JARVINEN, K., MECHOULAM, R., BREUER, A. & JARVINEN, T. (2002). Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci., 43, 3216-3222.
47. LAMBERT, D.M., DIPAOLO, F.G., SONVEAUX, P., KANYONYO, M., GOVAERTS, S.J., HERMANS, E., BUEB, J., DELZENNE, N.M. & TSCHIRHART, E.J. (1999). Analogues and homologues of N-palmitoylethanolamide. a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta. 1440, 266-274.
48. LAMBERT, D.M., VANDEVOORDE, S., JONSSON, K.O. & FOWLER, C.J. (2002). The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem., 9, 663-674.
49. LEGGETT, J.D., ASPLEY, S., BECKETT, S.R., D'ANTONA, A.M. & KENDALL, D.A. (2004). Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br. J. Pharmacol., 141, 253-262.
50. MACCARRONE, M., ATTINA, M., BARI, M., CARTONI, A., LEDENT, C. & FINAZZI-AGRO, A. (2001). Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. J. Neurochem., 78, 339-348.
51. MACCARRONE, M., VANDERSTELT, M., ROSSI, A., VELDINK, G.A., VLIEGENTHART, J.F. & AGRO, A.F. (1998). Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem., 273, 32332-32339.
52. MARTINEZ-GONZALEZ, D., BONILLA-JAIME, H., MORALES-OTAL, A., HENRIKSON, S.J., VELAZQUEZ-MOCTEZUMA, J. & PROSPERO-GARCIA, O. (2004). Oleamide and anandamide effects on food intake and sexual behavior of rats. Neuro. Lett., 364, 1-6.
53. MAURELLI, S., BISOGNO, T., DE PETROCELLIS, L., DILUCCIA, A., MARINO, G. & DI MARZO, V. (1995). Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett., 377, 82-86.
54. MAZZARI, S., CANELLA, R., PETRELLI, L., MARCOLONGO, G. & LEON, A. (1996). N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol., 300, 227-236.
55. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R., COMPTON, D.R., PERTWBEE, R.G., GRIFFIN, G., BAYEWITCH, M., BARG, J. & VOGEL, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
56. MECHOULAM, R., FRIDE, E. & DIMARZO, V. (1998). Endocannabinoids. Eur. J. Pharmacol., 359, 1-18.
57. MILMAN, G., MAOR, Y., HOROWITZ, M., GALLILY, R., HANUS, L. & MECHOULAM, R. (2004). Arachidonoyl-serine, an endocannabinoids-like bioactive constituent of rat brain. ICRS Abstracts Online 133.
58. OKA, S., TSUCHIE, A., TOKUMURA, A., MURAMATSU, M., SUHARA, Y., TAKAYAMA, H., WAKU, K. & SUGIURA, T. (2003). Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem., 85, 1374-1381.
59. PINTO, J.C., POTIE, F., RICE, K.C., BORING, D., JOHNSON, M.R., EVANS, D.M., WILKEN, G.H., CANTRELL, C.H. & HOWLETT, A.C. (1994). Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol., 46, 516-522.
60. PREMKUMAR, L.S., QI, Z.-H., VAN BUREN, J. & RAISINGHANI, M. (2004). Enhancement of potency and efficacy of NAD A by PKC-mediated phosphorylation of vanilloid receptor. J. Neurophys., 91, 1442-1449.
61. PRUSAKIEWICZ, J.J., KINGSLEY, P.J., KOZAK, K.R. & MARNETT, L.J. (2002). Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. Biochem. Biophys. Res. Commun., 296, 612-617.
62. RAKHSHAN, F., DAY, T.A., BLAKELY, R.D. & BARKER, E.L. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J. Pharmacol. Exp. Ther., 292, 960-967.
63. RANDALL, M.D., KENDALL, D.A. & O'SULLIVAN, S. (2004). The complexities of the cardiovascular actions of cannabinoids. Br. J. Pharmacol., 142, 20-26.
64. RODRIGUEZ DE FONSECA, F., NAVARRO, M., GOMEZ, R., ESCUREDO, L., NAVA, F., FU, J., MURILLO-RODRIGUEZ, E., GIUFFRIDA, A., LOVERME, J., GAETANI, S., KATHURIA, S., GALL, C. & PIOMELLI, D. (2001). An anorexic lipid mediator regulated by feeding. Nature, 414, 209-212.
65. ROSS, R.A. (2003). Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140, 790-801.
66. SAGAR, D.R., SMITH, P.A., MILLNS, P.J., SMART, D., KENDALL, D.A. & CHAPMAN, V. (2004). TRPV1 and CB1 receptor-mediated effects of the endovanilloid/endocannabinoids N-arachidonoyldopamine on primary afferent fibre and spinal cord neuronal responses in the rat. Eur. J. Neurol., 20, 175-184.
67. SALZET, M. & STEFANO, G.B. (2002). The endocannabinoid system in invertebrates. Prostaglandins Leukot. Essent. Fatty Acids, 66, 353-361.
68. SANCHO, R., MACHO, A., DE LA VEGA, L., CALZADO, M.A., FIEBICH, B.L., APPENDING, G. & MUNOZ, E. (2004). Immunosuppressive activity of endovanilloids N-arachidonoyl-dopamine inhibits activation of the NF-κB, NFAT. and activator protein 1 signaling pathways. J. Immunol., 172, 2341-2351.
69. SCHMID, H.H. & BERDYSHEV, E.V. (2002). Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot. Essent. Fatty Acids, 66, 363-376.
70. SCHUEL, H., BURKMAN, L.J., LIPPES, J., CRICKARD, K., FORESTER, E., PIOMELLI, D. & GIUFFRIDA, A. (2002). N-acylethanolamines in human reproductive fluids. Chem. Phys. Lipids, 121, 211-227.
71. SHESKIN, T., HANUS, L., SLAGER, J., VOGEL, Z. & MECHOULAM, R. (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 40, 659-667.
72. SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
73. THOMAS, E.A., CRAVATT, B.F., DANIELSON, P.E., GILULA, N.B. & SUTCLIFFE, J.G. (1997). Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J. Neurosci. Res., 50, 1047-1052.
74. TOTH, A., KEDEI, N., WANG, Y. & BLUMBERG, P.M. (2003). Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci., 73, 487-498.
75. WALTER, L. & STELLA, N. (2004). Cannabinoids and neuroinflammation. Br. J. Pharmacol., 141, 775-785.
76. YOST, C.S., HAMPSON, A.J., LEONOUDAKIS, D., KOBLIN, D.D., BORNHEIM, L.M. & GRAY, AT. (1998). Oleamide potentiates benzodiazepine-sensitive gamma-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth. Analg., 86, 1294-1300.
77. YU, M., IVES, D. & RAMESHA, C.S. (1997). Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem., 22, 21181-21186.